Intervention not reported
HD‐ICS/LABA (Direct evidence; 3 RCTs; 3700 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
1 finding from 1 review
Intervention not reported
Severe exacerbations ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 815(1 RCT)
The intervention showed no clear difference in severe exacerbations ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants:… (low certainty).
1 finding from 1 review
Intervention not reported
MD‐TRIPLE (Direct evidence; 3 RCTs; 3063 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
1 finding from 1 review
Intervention not reported
HD‐TRIPLE (Direct evidence; 2 RCTs; 1916 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
1 finding from 1 review
Intervention not reported
MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Total studies: 5 RCTs Total Participants: 7391 · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
1 finding from 1 review
Intervention not reported
HD‐ICS/LABA (Direct evidence; 2 RCTs; 2817 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
1 finding from 1 review
Intervention not reported
MD‐TRIPLE (Direct evidence; 2 RCTs; 2237 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
1 finding from 1 review
Intervention not reported
HD‐TRIPLE (Direct evidence; 1 RCT; 1088 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
1 finding from 1 review
Intervention not reported
MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Outcome№ of participants(studies)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
ACQ responders at 6 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 3700(3 RCTs)
The intervention showed no clear difference in ACQ responders at 6 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of… (moderate certainty).
1 finding from 1 review
All‐cause mortality · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care showed no clear difference in all‐cause mortality compared with standard care (with or without placebo) (low certainty).
1 finding from 1 review
Admission to hospital or death · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care probably leads to lower admission to hospital or death compared with standard care (with or without placebo) (moderate certainty).
1 finding from 1 review
Resolution of symptoms · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care probably leads to higher symptom resolution: all initial symptoms resolved at day 14 compared with standard care (with or without placebo) (moderate certainty).
1 finding from 1 review
Time to symptom resolution · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care showed no clear difference in symptom resolution: duration to symptoms resolved compared with standard care (with or without placebo) (low certainty).
1 finding from 1 review
Serious adverse events · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
It is very uncertain whether inhaled corticosteroids plus standard care changes serious adverse events compared with standard care (with or without placebo) (very low certainty).
1 finding from 1 review
Adverse events · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care showed no clear difference in adverse events compared with standard care (with or without placebo) (low certainty).
1 finding from 1 review
Infections · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care showed no clear difference in infections compared with standard care (with or without placebo) (low certainty).
1 finding from 1 review
Exacerbations: number of people experiencing moderate or severe exacerbations · treatment for asthma in adults and children with asthma and GORD
Medical or surgical intervention, or both, for gastro‐oesophageal… showed no clear difference in number of participants with moderate/severe acute exacerbations… compared with nil intervention, delayed intervention control, or placebo (low certainty).
1 finding from 1 review